Donnatal

Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide


Concordia Pharmaceuticals Inc.
Human Prescription Drug
NDC 59212-423
Donnatal also known as Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide is a human prescription drug labeled by 'Concordia Pharmaceuticals Inc.'. National Drug Code (NDC) number for Donnatal is 59212-423. This drug is available in dosage form of Elixir. The names of the active, medicinal ingredients in Donnatal drug includes Atropine Sulfate - .0194 mg/5mL Hyoscyamine Sulfate - .1037 mg/5mL Phenobarbital - 16.2 mg/5mL Scopolamine Hydrobromide - .0065 mg/5mL . The currest status of Donnatal drug is Active.

Drug Information:

Drug NDC: 59212-423
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Donnatal
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Concordia Pharmaceuticals Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Elixir
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ATROPINE SULFATE - .0194 mg/5mL
HYOSCYAMINE SULFATE - .1037 mg/5mL
PHENOBARBITAL - 16.2 mg/5mL
SCOPOLAMINE HYDROBROMIDE - .0065 mg/5mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 30 Dec, 1980
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 18 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2024
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Concordia Pharmaceuticals Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1046787
1046924
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:451IFR0GXB
03J5ZE7KA5
F2R8V82B84
YQE403BP4D
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Anticholinergic [EPC]
Cholinergic Antagonists [MoA]
Cholinergic Muscarinic Antagonist [EPC]
Cholinergic Muscarinic Antagonists [MoA]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.
DEA Schedule:CIV
This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
59212-423-04118 mL in 1 BOTTLE (59212-423-04)30 Dec, 1980N/ANo
59212-423-1010 mL in 1 BOTTLE (59212-423-10)30 Dec, 1980N/ANo
59212-423-16473 mL in 1 BOTTLE (59212-423-16)30 Dec, 1980N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Donnatal phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide phenobarbital phenobarbital hyoscyamine sulfate hyoscyamine atropine sulfate atropine scopolamine hydrobromide scopolamine glycerin alcohol water sorbitol sucrose saccharin sodium fd&c blue no. 1 fd&c red no. 3 artificial and natural grape donnatal phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide phenobarbital phenobarbital hyoscyamine sulfate hyoscyamine atropine sulfate atropine scopolamine hydrobromide scopolamine glycerin alcohol water sorbitol sucrose saccharin sodium fd&c yellow no. 5 fd&c blue no. 1 natural mint

Drug Interactions:

Drug interactions phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal effect. when the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.

Indications and Usage:

Indications and usage based on a review of this drug by the national academy of sciences-national research council and/or other information, fda has classified the indications as follows: "possibly" effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. final classification of the less-than-effective indications requires further investigation. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications.

Warnings:

Warnings donnatal® elixir can cause fetal harm when administered to a pregnant woman. animal reproduction studies have not been conducted with donnatal® elixir. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. in the presence of a high environmental temperature, heat prostration can occur with belladonna alkaloids (fever and heatstroke due to decreased sweating). diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. in this instance, treatment with this drug would be inappropriate and possibly harmful. donnatal® elixir may produce drowsiness or blurred vision. the patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work. phenobarbital may decrease the effect of a
nticoagulants, and necessitate larger doses of the anticoagulant for optimal effect. when the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased. phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs. since barbiturates are metabolized in the liver, they should be used with caution and initial doses should be small in patients with hepatic dysfunction.

General Precautions:

General use with caution in patients with: autonomic neuropathy hepatic or renal disease hyperthyroidism coronary heart disease congestive heart failure cardiac arrhythmias tachycardia hypertension belladonna alkaloids may produce a delay in gastric emptying (antral stasis) which would complicate the management of gastric ulcer. do not rely on the use of the drug in the presence of complication of biliary tract disease. theoretically, with overdosage, a curare-like action may occur. donnatal® elixir – mint contains fd&c yellow no. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. although the overall incidence of fd&c yellow no. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Dosage and Administration:

Dosage and administration the dosage of donnatal® elixir should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse effects. donnatal® elixir. adults: one or two teaspoonfuls of elixir three or four times a day according to conditions and severity of symptoms. pediatric patients: may be dosed every 4 to 6 hours. use a pediatric dosing device or oral syringe to measure the dose. starting dosage body weight every 4 hours every 6 hours 10 lb. (4.5 kg) 0.5 ml 0.75 ml 20 lb. (9.1 kg) 1 ml 1.5 ml 30 lb. (13.6 kg) 1.5 ml 2 ml 50 lb. (22.7 kg) 2.5 ml 3.75 ml 75 lb. (34 kg) 3.75 ml 5 ml 100 lb. (45.4 kg) 5 ml 7.5 ml

Contraindications:

Contraindications glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic megacolon; myasthenia gravis; hiatal hernia associated with reflux esophagitis; in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement.

Adverse Reactions:

Adverse reactions adverse reactions may include xerostomia; urinary hesitancy and retention; blurred vision; tachycardia; palpitation; mydriasis; cycloplegia; increased ocular tension; loss of taste sense; headache; nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; musculoskeletal pain; severe allergic reaction or drug idiosyncrasies, including anaphylaxis, urticaria, and other dermal manifestations; and decreased sweating. acquired hypersensitivity to barbiturates consists chiefly in allergic reactions that occur especially in persons who tend to have asthma, urticaria, angioedema, and similar conditions. hypersensitivity reactions in this category include localized swelling, particularly of the eyelids, cheeks, or lips, and erythematous dermatitis. rarely, exfoliative dermatitis (e.g. stevens-johnson syndrome and toxic epidermal necrolysis) may be caused by phenobarbital and can prove fatal. t
he skin eruption may be associated with fever, delirium, and marked degenerative changes in the liver and other parenchymatous organs. in a few cases, megaloblastic anemia has been associated with the chronic use of phenobarbital. phenobarbital may produce excitement in some patients, rather than a sedative effect. to report suspected adverse reactions, contact concordia pharmaceuticals at 1-877-370-1142 or the fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Drug Interactions:

Drug interactions phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal effect. when the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.

Use in Pregnancy:

Pregnancy animal reproduction studies have not been conducted with donnatal® elixir. there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks ( see warnings ).

Geriatric Use:

Geriatric use elderly patients may react with symptoms of excitement, agitation, drowsiness, and other untoward manifestations to even small doses of the drug.

Overdosage:

Overdosage the signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot and dry skin, dizziness, dryness of the mouth, difficulty in swallowing, and cns stimulation. treatment should consist of gastric lavage, emetics, and activated charcoal. if indicated, parenteral cholinergic agents such as physostigmine or bethanechol chloride should be used.

dependence:

Dependence in patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsions.

Description:

Description donnatal ® elixir - grape each 5 ml (teaspoonful) of elixir (alcohol not more than 23.8%) contains: phenobarbital, usp.............................. 16.2 mg hyoscyamine sulfate, usp............... 0.1037 mg atropine sulfate, usp...................... 0.0194 mg scopolamine hydrobromide, usp.... 0.0065 mg inactive ingredients purified water, glycerin, sorbitol, ethyl alcohol, sucrose, saccharin sodium, artificial and natural grape flavor, fd&c red #3, and fd&c blue #1.

Donnatal ® elixir - mint each 5 ml (teaspoonful) of elixir (alcohol not more than 23.8%) contains: phenobarbital, usp.............................. 16.2 mg hyoscyamine sulfate, usp............... 0.1037 mg atropine sulfate, usp...................... 0.0194 mg scopolamine hydrobromide, usp.... 0.0065 mg inactive ingredients purified water, glycerin, sorbitol, ethyl alcohol, sucrose, saccharin sodium, natural mint flavor, fd&c yellow #5, and fd&c blue #1.

Clinical Pharmacology:

Clinical pharmacology this drug combination provides natural belladonna alkaloids in a specific, fixed ratio combined with phenobarbital to provide peripheral anticholinergic/antispasmodic action and mild sedation.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility long-term studies in animals have not been performed to evaluate carcinogenic potential.

How Supplied:

How supplied donnatal® elixir - grape is a purple colored, grape flavored liquid. 4 fl oz (118 ml) bottles- ndc 59212-423-04. 1 pint (473 ml) bottles- ndc 59212-423-16. donnatal® elixir - mint is a green colored, mint flavored liquid. 4 fl oz (118 ml) bottles- ndc 59212-422-04. 1 pint (473 ml) bottles- ndc 59212-422-16. avoid freezing store donnatal® elixir at 20º- 25ºc (68º - 77ºf) [see usp controlled room temperature]. protect from light and moisture. dispense in a tight, light-resistant container as defined in the usp using a child-resistant closure. dea exempt product mfd. for: concordia pharmaceuticals distributed by: amdipharm limited 17 northwood house dublin 9, ireland revised:02/20

Information for Patients:

Information for patients donnatal® elixir may produce drowsiness or blurred vision. the patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work.

Package Label Principal Display Panel:

Principal display panel - donnatal elixir - grape, 4 oz ndc 59212-423-04 4 fl oz donnatal ® (phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide) elixir grape flavored each 5 ml (1 teaspoonful) contains: phenobarbital, usp.............................. 16.2 mg hyoscyamine sulfate, usp............... 0.1037 mg atropine sulfate, usp...................... 0.0194 mg scopolamine hydrobromide, usp.... 0.0065 mg alcohol not more than 23.8% do not use if tamper-evident seal under cap is broken or missing. rx only 4oz-grape-bottle-label

Principal display panel - donnatal elixir - mint, 4 oz ndc 59212-422-04 4 fl oz donnatal ® (phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide) elixir mint flavored each 5 ml (1 teaspoonful) contains: phenobarbital, usp.............................. 16.2 mg hyoscyamine sulfate, usp............... 0.1037 mg atropine sulfate, usp...................... 0.0194 mg scopolamine hydrobromide, usp.... 0.0065 mg alcohol not more than 23.8% do not use if tamper-evident seal under cap is broken or missing. rx only 4oz-mint-bottle-label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.